FirstTake on Pharma - Pharma News and Analysis Podcast podkast

The FirstTake Podcast – Gilead’s oncology strategy under the spotlight

Do tyłu o 15 sekund
Do przodu o 15 sekund
On this week’s episode FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss why Gilead is getting flak for a positive cancer drug study, what’s gone wrong at bluebird bio and why the FDA has been so quick to expand approval of Bristol Myers Squibb’s Opdivo for the treatment of neoadjuvant lung cancer.

Więcej odcinków z kanału "FirstTake on Pharma - Pharma News and Analysis Podcast"